Schlüsselwörter
Stammzellen · Knochenmark · Gewebegesetz · Transplantation · Transfusion · Qualitätsmanagement -system · Sicherheit Zusammenfassung Zelltherapeutika tragen beträchtlich zur optimalen Behandlung von Patienten mit hämatologischen Erkrankungen wie z.B. Leukämien und nichthämatologischen Krankheitsbildern bei. In den letzten 50 Jahren wurde insbesondere die Transplantation autologer bzw. allogener Stammzellen zu einer gut etablierten Standardtherapie, die bei mehr als 50 000 Patienten/Jahr zu einer Linderung oder Heilung ihrer Erkrankung führt. In naher Zukunft wird der gegenwärtige Fortschritt in der Grundlagenforschung der Stammzellen und Immunbiologie die klinische Einführung neuer fortschrittlicher Zelltherapien einschließlich gentherapeutischer Ansätze ermöglichen. Parallel hierzu hat die europäische und deutsche Gesetzgebung die Notwendigkeit von internationalen Vorschriften zur besseren Standardisierung und Harmonisierung von Stammzelltransplantaten, weiterfüh-renden Zelltherapeutika als auch von zahlreichen Gewebezubereitungen im wachsenden Markt der Regenerativen Medizin erkannt. Die im März 2004 im Europäischen Parlament debattierte und verabschiedete Geweberichtlinie 2004/23/EG und deren nationale Überführung in das deutsche Gewebegesetz, welches im Juli 2007 in Kraft getreten ist, definieren die Qualitäts-und Sicherheitsstandards für die Spende, Beschaffung, Testung, Weiterverarbeitung, Konservierung, Lagerung und Verteilung von menschlichen Geweben und Zellen. Diese Standards sind von großer Bedeutung, um eine effiziente Vorbeugung der Übertragung von viralen und nichtviralen infektiösen Pathogenen zu gewähr-leisten und die gleichen Sicherheitsstandards wie bei der Versorgung der Bevölkerung mit Blutkomponenten zu erzielen. Dieser Übersichtsartikel diskutiert die Vor-und Nachteile der neuen Gesetzgebung und spricht sich dafür aus, die administrativen und regulativen Anforderungen in vernünf-tigen Grenzen zu halten und innovative Ansätze in der Zelltherapie der europäischen Bevölkerung anzubieten.
Introduction
The law of the European Community is usually specified in directives such as Directive 2001/83/EC ('Medicinal Products for Human Use') [1] and Directive 2002/98/EC ('Blood Directive') [2] which are both well-known to institutions that produce blood components from voluntarily donated blood based on pharmaceutical standards (Good Manufacturing Practice (GMP)). In spring 2004, an additional directive, the Tissues and Cells Directive 2004/23/EC [3], was passed in the European Parliament. All member states of the European Community were obliged to transpose Directive 2004/23/EC into their national legislature within a period of 2 years. The mandatory implementation serves to provide a harmonization within all member states of the EU so that almost equivalent rights can be guaranteed for a comparable and risk-benefitbalanced access to novel therapies from the emerging field of regenerative medicine. For Germany, enactment started with the implementation of a special 'Tissue Act' which came into force in July 2007 [4] . This Tissue Act is not a law on its own, but leads to significant amendments of the Medicinal Products Act [5] , the Transplantation Act [6] , and the Transfusion Act [7] . These acts together with the German Drug Act (Arzneimittelgesetz (AMG); 12th and 14th amendments) and the German Ordinance for the Production of Medicinal Products and Active Substances (Arzneimittel-und Wirkstoffherstellungsverordnung; AMWHV) [8] represent the most important legal stipulations governing organs, blood components, tissues and cells (table 1) . For more detail see von Auer [9, 10] . As published by others [11] , there are substantial differences between blood components, stem cell as well tissue transplants and synthetic pharmaceuticals so that the Council of Europe made arrangements to separate clearly the legal framework for blood components from that for classical pharmaceuticals. In this view the German Tissue Act might contradict the political claim to keep the legal complexity in reasonable limits.
General Implications of the German Tissue Act for Tissue and Cell Preparations
The Directive 2004/23/EC (published in November, 2007, come into force in December, 2008) [3] includes minimum standards that are designed to ensure high quality and safety margins for human tissues and cell preparations released for clinical application in humans. The demands for standardization cover the donation, procurement, testing, processing, preservation, storage, and distribution of human tissues and cells (table 2) . The German Tissue Act exceeds these minimum requirements and is designed to aspire to the highest level of quality for supplying the German population with safe tissue and cell preparations while, at the same time, keeping restrictions in mind regarding the safety of blood supplies that first came to light when the HIV crisis was in full flow during the early 1990s. Despite the critique of the German Medical Association (Bundesärztekammer) and various medical societies and despite of other statements [12] , the final German Tissue Act still defines tissues and cell preparations as pharmaceutical drugs governed by the German Drug Act. Amendments to this act (e.g. Section 4a) highlight the need for high standards in quality and safety and close most of the loopholes that might otherwise allow operation outside national drug legislation in the field of local tissue banking and tissue engineering [13, 14] . The German Tissue Law seems to be heading in the direction that donated tissues, including stem cell preparations, must be subject to the same strict regulations as pharmaceutical products, preventing the most serious adverse effects of allogeneic tissue transplants, that is the transmission of Musculoskeletal tissues (bone, muscle, tendon, soft tissue) Cornea and sklera Epidermis Cardiovascular tissues (vessel, heart valve, pericardial tissue) Others (amnion, placenta, embryonic/fetal tissue) viral and nonviral infectious pathogens. Whenever possible, a validated inactivation procedure should included in the manufacturing process [15, 16] . The term 'tissue' for medicinal purposes includes all tissue components from a human body that are not defined as organs ('functionally intact unit') as listed in table 3, which also includes single cells. Human bone marrow, fetal cells/tissues and germ cells (oocytes and sperms) are all listed as 'tissues'. Whole blood, blood components, and consequently stem cells derived from peripheral blood or cord blood are excluded from this definition. Other specialized cells such as immunocompetent cells derived from peripheral blood are also covered by this exclusion criterion. It seems appropriate to alert potential applicants for novel therapeutic agents that another EU treaty for Advanced Therapy Medicinal Product Regulation (1394/2007/EC) [17] shall be coming up in December 2008, and that this shall contain deadlines for commercially distributed medicinal products in the fields of gene therapy, somatic cell therapy and tissue engineering. Deadlines for the transition into marketing authorization are as follows: -for gene therapy medicinal products December 2012 -for somatic cell therapy medicinal products December 2012 -for tissue engineered medicinal products December 2013. The term 'tissue preparation' refers to unmanipulated tissues per se as well as any novel preparations whose preparation is based on such primary tissues. Such tissue preparations are pharmaceuticals according to section 4 (30) of the German Drug Act. However, there are two major exceptions: i) germ cells such as oocytes (fertilized or nonfertilized) or, spermatozoa and ii) embryos in toto. Now that the German Tissue Act has come into force, such tissues, currently defined as pharmaceuticals, usually require national approval (so-called 'Genehmigungsverfahren') which in principle is comparable, although somewhat simplified, to the well-established national licensing procedure for blood components seeking postmarketing approval from the national authorities (Paul Ehrlich Institute) (so-called 'Zulassungsverfahren') ( fig. 1 ). The extent to which national approvals for tissue preparations have contributed to a significantly improved quality and essentially higher safety profile for each treated patient and the extent to which these efforts are well-balanced in the light of the well-known overregulation and bureaucracy at both the national and European levels is still a matter of some dispute. Emerging therapeutic options using tissue-engineered grafts have required timely national requirements to ensure a high quality of treatment and approximately equivalent safeguards for all citizens of the European Union, especially in preventing the transmission of tissue-or transplant-associated infectious pathogens. Keeping this spirit in mind, the German Tissue Act in fact represent a systematic continuation of the tradition of national legislation that has prevailed over past decades. Not surprisingly, legal regulation of tissue and cell preparations now considers the highly positive experiences obtained with the standardization and licensing of blood components for ensuring the highest quality and optimal implementation of a local and national system for surveillance. Under certain circumstances the above-mentioned permissions are not required, e.g. if the tissue preparation is manufactured for an individual patient under the direct professional responsibility of the same physician who applies this tissue preparation, or if the tissue is immediately taken from the patient and retransferred within the same treatment cycle. Examples for such tissue preparations are autologous transplants which are transposed within a (surgical) treatment e.g. cranium, pancreatic insulin-producing beta-cells, and parathyroids. The application procedure for tissues using the standards of Common Technical Documents (CTD module 1-5), the review process, and the final decision-making by the national authorities is summarized in another article of this special issue of TRANSFUSION MEDICINE AND HEMOTHERAPY [18] . In addition, an overview of CTD modules applicable to any kind of stem cell preparations is given in figure 2. cell mobilization into the circulation and the their homing within the bone marrow niche. The final version of this statement shall include a detailed assessment of the pharmacokinetic and toxicological profile of dimethylsulfoxide (DMSO) written by two experts in this field. DMSO is the most relevant additive in all cyropreserved stem cell preparations and serves as cyroprotectant for most types of nucleated cells. The review processes for the CTDs and co-submitted documents being undertaken by national authorities are still ongoing, and decisions are not expected before the turn of the year. At this point it should be stated that legislators have now succeeded in closing a longstanding loophole in the specification of hematopoietic stem cell transplantation products. Institutions which exclusively manufacture stem cell products may no longer benefit from the favorable circumstances of the past and might unwillingly accept that they are now confronted with a huge administrative burden that now includes declarations of product specifications, provision of efficacy and safety data, and the submission of standard operating procedures, common technical documents and other relevant documents (standards for look-back procedures, systems for pharmacovigilance and risk management). Tissue banks and stem cell transplantation centers are well advised to focus on comprehensive and robust quality assurance in all areas of donating, testing, procurement and preservation. The professional handling of all such matters is traditionally well-established in pharmaceutical companies which release their cellular blood components and coagulation products on the basis of company-related licenses that ensure high-level quality standards and safety margins. Thus, knowledge of the legal framework and correctness in dealing with local and national authorities are both good prerequisites for blood centers, whether it be for meeting new demands or for offering themselves as competent cooperation partners. Nevertheless, legislators and national authorities should carefully balance the practicality of regulations that have just come into effect through the German Tissue Act. The efforts and expenses to meet these new requirements have to keep in reasonable limits. The transplantation of hematopoietic stem cells has for some time been a globally accepted treatment option for patients with malignancies and other congenital disorders such as primary immune disorders. As highlighted by Frederick Appelbaum [19] , 2007 marked the 50th anniversary of the initial report by Thomas et al. [20] on the intravenous infusion of bone marrow after a radio-/chemotherapy. Since that time, and after overcoming severe clinical restrictions in the 1960s and 1970s, more than 50,000 people per year have now undergone hematopoietic stem cell transplantations of which almost 20,000 are allogeneic transplantations using related or unrelated donors. Until now more than 11 million HLA-typed donors and cord bloods are available in national registries such as the Bone Marrow Donor Worldwide Registry. For European patients, in approximately three of four cases an acceptable HLA-matched donor could be identified with more than 50% probability of a 10/10 match, which means that the patient and donor share the same five alleles on both haplotypes (HLA-A,-B-C, DRB1 and DQB1) [21] . Based on these facts and the urgent need for autologous and allogeneic stem cell transplantations for life-threatening diseases, neither the harmonization of the European Law nor the accentuation of national legal requirements should seriously endanger patients' lives or their right to receive an optimal treatment in time. Therefore, the introduction of a mandatory demand for approvals to manufacture hematopoietic stem cell products for transplant purposes should lead neither to a bottleneck nor a lengthening of waiting lists for potential transplant candidates. In addition, most, if not all, of the national centers involved in stem cell transplantations are registered and certified by local authorities and international accreditation societies that ensure the application of GMP standards and the use of an appropriate quality management system within the respective institutions. Keeping this in mind, all responsible individuals should make the boldest attempts to prevent the spirit of the German Tissue Act being lost in red tape, and the patients' interests being ride roughshod over. Furthermore, all participants will continue to learn that stem cell transplantations represent only one component of a patient's individualized treatment schedule. A broad variety of stem cell preparations now exist for optimizing a patient's fight against cancer, improving disease-free survival and increasing the overall quality of life. Stem cells preparations are not comparable to blood components such as red blood cell units which are collected and produced in millions of units per annum using 'universal' manufacturing standards and standardized final product specifications. The national authorities in Germany have recognized the specific properties of stem cell preparations and their individual production on a patientto-patient basis. This is especially true for unrelated allogeneic transplantations in which the best HLA-matched donor has to be identified to prevent graft-versus-host disease and graft failure. The tissue compatibility is determined by a set of high polymorphic genes of the HLA complex. Nowadays molecular DNA typing methods using PCR technology and DNA sequencing allow for HLA typing on a high-resolution level resulting in an improved selection of unrelated donors which contributes to a better clinical outcome [21] . Consistently with this patient-related perspective, the Paul Ehrlich Institute now demands a declaration of quality-associated properties of stem cell preparations rather than any final and preset product specifications. These quality-related properties are summarized in table 6. By applying this modus operandi, the Paul Ehrlich Institute addresses the idiosyncrasies of stem cell preparations that require discretion to be exercised. The optimal endpoint for assuring the quality of a transplanted product is the complete engraftment of hematopoiesis to a patient. From this viewpoint, both the duration of aplasia until recovery of leukocyte and platelet numbers (>500 neu-trophils/μl and >20 platelets/nl) and the timeframe over which independence from exogenous blood supplies (red blood cell units and platelet concentrates) is achieved are of high relevance for objectively assessing the hematopoietic reconstitution in vivo. The quality-associated properties mentioned above are in vitro parameters that might serve as adequate surrogate markers for assessing this engraftment potential. Indeed, the accurate determination of the CD34+ stem cell dose represents the most important analysis since it directly correlates with hematological engraftment. Nowadays, the singleplatform flow-cytometric analysis of CD34+ cell counts based on fluorescent microbeads is a well established procedure for enumerating stem cells in accordance with internationally accepted ISHAGE standards [22] . This platform allows for the simultaneous measurement of cell viability using the nuclear stain 7-AAD which specifically intercalates into the DNA of dead cells that are unable to contribute to the desired hematopoietic engraftment. Thus, the identification and quantification of 7-AAD+ events should be directly related to the total number of nucleated cells (approximately all leukocytes) or, more preferably, the subpopulation of CD34+ target cells. Ultimately, the concentration of viable CD34+ stem cells in the thawed transplant products (or thawed aliquots of representative samples) might be a suitable in vitro parameter that correlates with in vivo engraftment and may also be sufficient for predicting the outcome of a hematopoietic reconstitution. Nevertheless, the all pre-analytical steps involving thawed, DMSO containing samples, such as washing or dilution, and the subsequent flow-cytometric stem cell quantification using anti-CD34 antibodies have to be standardized and validated, especially for the purposes of ensuring that cyropreserved and subsequently thawed stem cells express stable CD34 antigens on the cell surface that is not masked for unknown reasons on freshly thawed cells. Apart from the above discussed flow-cytometric approaches, short-term culture assays are also widely used for estimating the proliferation capacity of myeloid and erythroid progenitor cells [23] . Under optimized growth and differentiation conditions, such progenitors are usually able to generate in vitro lineage-specific colonies such as CFU-GM and BFU-E/CFU-E. In the meantime, growth of CFU-GM per se serves as a useful parameter for revealing that at least a proportion of the viable CD34+ cells collected for transplantation purposes are cell-cycle active progenitors that divide into daughter cells and are able to contribute to the clonal expansion of mature cells. These progenitor cells are lineage-restrictive rather than immature and pluripotent stem cells. As such it is doubtful whether colony-forming cells are able to function as surrogates for true pluripotent stem cells, or indeed as indicators for hematopoietic reconstitution over the long term. In this context, any attempt to quantify CFU-GM content in transplant products is restricted by the huge variety of growth factor-containing media supplements and the resulting poor standardization of such cell culture systems, including also microscopic evaluation. Historically, it is well known that the CFU-GM content correlates with short-term hematopoietic engraftment even though the current standard of CD34+ cell concentration/kg body weight is more precise. Furthermore, approximately 10-20% of CD34+ cells that build up CFU-GM colonies depend on the culture medium used as well as how and how many CD34+ cells are seeded onto the culture dishes.
As a result, the use of time-consuming short-term culture assays and its sophisticated microscopic evaluation as an addition to the flow-cytometric quantification of CD34+ cells does not provide a more proper assessment of the quality and safety of stem cell products. A mandatory and regular usage of short-term culture assays to indicate quality therefore cannot be generally recommended.
Closing Remarks
Taking these findings together, the selection of applicable in vitro parameters and underlying methodologies are of prime importance for improving the quality and safety of stem cell preparations as regards their unique potential to reconstitute both the hematopoietic and immune systems in their entirety after transplantation. Blood centers, pharmaceutical companies, and national authorities must focus their attention on the accurate validation of methods used for the manufacturing, testing, and characterization of the essential quality-related properties of stem cell preparations. Combined with all other requirements that shall become mandatory following the enactment of European Directive 2004/23/EC and the German Tissue Act, these efforts will be of great value for standardizing and improving quality and safety of the manufacture of autologous and allogeneic stem cell transplantations in order to a achieve a standard as high as that already guaranteeing the population's blood supply for years. 
